Insider Selling: John Stuart Patton Sells 75,000 Shares of Halozyme Therapeutics Stock (HALO)
Halozyme Therapeutics (NASDAQ:HALO) Director John Stuart Patton unloaded 75,000 shares of Halozyme Therapeutics stock on the open market in a transaction dated Monday, September 16th. The stock was sold at an average price of $9.13, for a total transaction of $684,750.00. Following the completion of the sale, the director now directly owns 155,000 shares in the company. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on HALO shares. Analysts at Jefferies Group cut their price target on shares of Halozyme Therapeutics (NASDAQ:HALO) from $4.50 to $4.00 in a research note to investors on Friday, August 2nd. They now have an “underperform” rating on the stock. Separately, analysts at Barclays Capital downgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from an “overweight” rating to an “equal weight” rating in a research note to investors on Friday, August 2nd. They now have a $8.00 price target on the stock, down previously from $9.00.
One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $7.93.
Shares of Halozyme Therapeutics (NASDAQ:HALO) traded down 0.49% during mid-day trading on Monday, hitting $9.10. The stock had a trading volume of 1,041,905 shares. Halozyme Therapeutics has a 52 week low of $4.80 and a 52 week high of $9.45. The stock has a 50-day moving average of $7.85 and a 200-day moving average of $6.9. The company’s market cap is $1.024 billion.
Halozyme Therapeutics (NASDAQ:HALO) last released its earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $14.50 million for the quarter, compared to the consensus estimate of $11.29 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was up 91.9% on a year-over-year basis. Analysts expect that Halozyme Therapeutics will post $-0.68 EPS for the current fiscal year.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.